Health care stocks were steady-to-lower pre-bell Monday as the Health Care Select Sector SPDR Fund (XLV) was flat and the iShares Biotechnology ETF (IBB) recently fell by 0.8%.
Novavax (NVAX) shares rose past 23% after the company said the US Food and Drug Administration has approved the Biologics License Application for its COVID-19 vaccine Nuvaxovid.
Intellia Therapeutics (NTLA) shares advanced by over 4% after the company said it received "positive" two-year follow-up data from an ongoing phase 1 trial of its investigational drug nexiguran ziclumeran for the potential treatment of hereditary transthyretin amyloidosis with polyneuropathy, a genetic disease associated with the liver.
Zai Lab (ZLAB) shares were up more than 2% after the company said the US Food and Drug Administration has granted fast-track designation to ZL-1310, the company's potential antibody-drug conjugate for the treatment of extensive-stage small cell lung cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.